By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Cellular Dynamics International said today it has closed on a Series B Preferred Stock financing round, raising $30 million.

The financing will be used by the Madison, Wis.-based pluripotent stem cell development firm to launch new iCell induced pluripotent stem cell lines, as well as iCell Endothelial Cells, iCell Neurons, and iCell Hepatocytes for biomedical and pharmaceutical drug development and safety research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.